Literature DB >> 4192571

Characteristics of a non-complement-dependent C3-reactive complex formed form factors in nephritic and normal serum.

E H Vallota, J Forristal, R E Spitzer, N C Davis, C D West.   

Abstract

When serum from a patient with membrano-proliferative glomerulonephritis and normal serum are mixed at 37 degrees C, C3 is rapidly broken down to two more rapidly migrating components. In the mixture, a heat-labile pseudoglobulin, designated as the C3 nephritic factor or C3NeF, reacts with a pseudogolbulin in the normal serum, designated as cofactor, to form a C3 inactivator. By analogy with the cobra venom factor, the C3 inactivator is most likely a complex of the nephritic factor and cofactor. The complex has been designated as the C3 lytic nephritic factor or C3LyNeF. The reaction which results in the Formation of C3LyNeF requires the presence of Mg(++), is highly temperature sensitive but occurs very rapidly at 37 degrees C. In 20 min at 37 degrees C, C3LyNeF can break down over 80% of the C3 in a mixture of normal and nephritic serum. The two-step reaction which leads to C3 breakdown has an optimum pH ranging from 6.0 to 9.0. Experiments employing serum depleted of C4 and C2, as well as certain characteristics of the C3NeF system provide evidence that C3 breakdown with nephritic serum is not dependent on complement-inactivating immune complexes or on the action of convertase (C4, 2). Data relating rate of C3 breakdown to the concentrations of C3NeF, C3, and C3LyNeF in the reaction mixture are similar to those for the reaction of enzyme with substrate. The biological significance of C3LyNeF in the production of glomerular inflammation has not been established.

Entities:  

Mesh:

Substances:

Year:  1970        PMID: 4192571      PMCID: PMC2138838          DOI: 10.1084/jem.131.6.1306

Source DB:  PubMed          Journal:  J Exp Med        ISSN: 0022-1007            Impact factor:   14.307


  29 in total

1.  Anticomplementary activity of sera from patients with connective tissue disease and normal subjects.

Authors:  J P Castanedo; R C Williams
Journal:  J Lab Clin Med       Date:  1967-02

2.  Antigenic determinants of human beta-1c and beta-1g-globulins.

Authors:  C West; N C Davis; J Forristal; J Herbst; R Spitzer
Journal:  J Immunol       Date:  1966-04       Impact factor: 5.422

3.  Study of human renal disease by immunofluorescent methods.

Authors:  W K Hadley; W Rosenau
Journal:  Arch Pathol       Date:  1967-04

4.  Antibody-complement complexes.

Authors:  W F Willoughby; M M Mayer
Journal:  Science       Date:  1965-11-12       Impact factor: 47.728

Review 5.  A molecular concept of immune cytolysis.

Authors:  H J Muller-Eberhard; U R Nilsson; A P Dalmasso; M J Polley; M A Calcott
Journal:  Arch Pathol       Date:  1966-09

6.  Routine immunohistology in renal diseases.

Authors:  K Lange; G Treser; I Sagel; A Ty; E Wasserman
Journal:  Ann Intern Med       Date:  1966-01       Impact factor: 25.391

7.  Evidence for in vivo breakdown of beta-10-globulin in hypocomplementemic glomerulonephritis.

Authors:  C D West; S Winter; J Forristal; J M McConville; N C Davis
Journal:  J Clin Invest       Date:  1967-04       Impact factor: 14.808

8.  Complement as a mediator of inflammation. 3. Purification of the activity with anaphylatoxin properties generated by interaction of the first four components of complement and its identification as a cleavage product of C'3.

Authors:  W D da Silva; J W Eisele; I H Lepow
Journal:  J Exp Med       Date:  1967-12-01       Impact factor: 14.307

9.  Formation and functional significance of a molecular complex derived from the second and the fourth component of human complement.

Authors:  H J Müller-Eberhard; M J Polley; M A Calcott
Journal:  J Exp Med       Date:  1967-02-01       Impact factor: 14.307

10.  The reaction mechanism of beta-1C-globulin (C'3) in immune hemolysis.

Authors:  H J Müllerèberhard; A P Dalmasso; M A Calcott
Journal:  J Exp Med       Date:  1966-01-01       Impact factor: 14.307

View more
  29 in total

1.  Membranoproliferative glomerulonephritis with C3NeF and genetic complement dysregulation.

Authors:  Valérie Leroy; Véronique Fremeaux-Bacchi; Michel Peuchmaur; Véronique Baudouin; Georges Deschênes; Marie-Alice Macher; Chantal Loirat
Journal:  Pediatr Nephrol       Date:  2010-12-25       Impact factor: 3.714

2.  The immunogloblin nature of nephritic factor (NeF).

Authors:  D M Scott; N Amos; J G Sissons; P J Lachmann; D K Peters
Journal:  Clin Exp Immunol       Date:  1978-04       Impact factor: 4.330

Review 3.  Bright's disease today: the pathogenesis and treatment of glomerulonephritis. 3.

Authors:  J S Cameron
Journal:  Br Med J       Date:  1972-10-28

Review 4.  The properdin pathway: an "alternative activation pathway" or a "critical amplification loop" for C3 and C5 activation?

Authors:  Richard A Harrison
Journal:  Semin Immunopathol       Date:  2017-11-22       Impact factor: 9.623

5.  The cofactors required by C3 nephritic factor to generate a C3 convertase in vitro.

Authors:  N Amos; J G Sissons; J F Girard; P J Lachmann; D K Peters
Journal:  Clin Exp Immunol       Date:  1976-06       Impact factor: 4.330

Review 6.  The role of antibody in the activation of the alternative complement pathway.

Authors:  W D Ratnoff; D T Fearon; K F Austen
Journal:  Springer Semin Immunopathol       Date:  1983

7.  Continuing C3 breakdown after bilateral nephrectomy in patients with membrano-proliferative glomerulonephritis.

Authors:  E H Vallota; J Forristal; R E Spitzer; N C Davis; C D West
Journal:  J Clin Invest       Date:  1971-03       Impact factor: 14.808

8.  Glomerular complement components in human glomerulonephritis.

Authors:  P J Verroust; C B Wilson; N R Cooper; T S Edgington; F J Dixon
Journal:  J Clin Invest       Date:  1974-01       Impact factor: 14.808

9.  C3 nephritic factor and hypocomplementaemia in a clinically healthy individual.

Authors:  A T Gewurz; S M Imherr; S Strauss; H Gewurz; C Mold
Journal:  Clin Exp Immunol       Date:  1983-10       Impact factor: 4.330

10.  Significance of urinary C3 excretion in glomerulonephritis.

Authors:  A D Cumming; D Thomson; A M Davidson; J S Robson
Journal:  J Clin Pathol       Date:  1976-07       Impact factor: 3.411

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.